Lithium orotate is marketed as a "natural" low-dose lithium supplement for mood, brain health, and neuroprotection. Prescription lithium carbonate (900-1,800mg/day, providing 170-340mg elemental lithium) is a first-line treatment for bipolar disorder. OTC lithium orotate provides 5-20mg elemental lithium per dose — 10-70x lower. Our research shows: (1) there are ZERO published RCTs of lithium orotate at OTC doses for any indication; (2) the claim that orotate delivers lithium more efficiently to the brain (requiring lower doses) was based on ONE rat study from 1986 and has never been replicated; (3) even at low doses, lithium has a NARROW therapeutic index — the difference between therapeutic and toxic doses is small. This is a pharmaceutical mineral being sold without physician monitoring.
Lithium modulates multiple neurological pathways: (1) GSK-3β inhibition — the primary mood-stabilizing mechanism; glycogen synthase kinase-3β regulates neuroplasticity, circadian rhythm, and apoptosis; (2) inositol monophosphatase (IMPase) inhibition — reduces inositol recycling, dampening overactive phosphoinositide signaling in mood circuits; (3) neuroprotective — increases BDNF, promotes neurogenesis in hippocampus, increases gray matter volume; (4) anti-suicidal — mechanism unclear but lithium reduces suicide risk independently of mood stabilization. The orotate salt was hypothesized to cross cell membranes more readily than carbonate (lipophilic carrier theory), but this has NOT been confirmed in any human pharmacokinetic study.
Reviewed by the Scan Dose Research Team and Clinical Advisory Board | Last updated:
Not medical advice. Based on published clinical research and systematic reviews.